Company News

Regenerative medicine company Orthocell (ASX:OCC) has announced it has received notification from the Australian Department of Health that its CelGro Dental has been included on the Prostheses List.

Emerging Australia oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) has announced a license agreement for its lead pipeline candidate Cantrixil (TRX-E-002-1).

Senior representatives of CSL appeared earlier this week before the ongoing Senate inquiry into the federal government's response to the COVID-19 pandemic.

Mesoblast (ASX:MSB) has raised US$110 million (A$138 million) via the issue of 60 million shares in a private placement led by a US investor group.

Researchers at the Brisbane-based QIMR Berghofer have discovered some of the ways COVID-19 damages the heart and identified a class of drugs that could potentially protect or reverse this injury.

An inspiring line-up of Australian and global keynotes and panels has been revealed as the AusMedtech 2021 conference programme is launched. 'AusMedtech 2021: Reimagine and reconnect' provides virtual half-day sessions across five days, 17 – 21 May, that represent Australia’s medtech industry.

Osprey Medical (ASX:OSP) has signed Independent Sales Agency agreements with Access Medical, Consolidated Medical Supplies and DriKot Medical that will expand its sales coverage in the US.

Australian clinical-stage synthetic cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has announced the expansion of its management team with the appointment of three executives in the US.

Health minister Greg Hunt has announced the federal government will invest $100 million in the development of new technologies to improve diagnosis and treatment of stroke, epilepsy and lung disease, including COVID-19.

Cynata Therapeutics (ASX:CYP), a clinical-stage biotechnology company specialising in cell therapeutics, has announced the initiation of a new study to investigate its Cymerus mesenchymal stem cells. 

AusBiotech welcomes the Government’s support of the biotech industry as it opens the first round of funding for bio-manufacturing and launches its Medical Products’ National Manufacturing Priority road map.

Opthea (ASX:OPT) says it has finalised the protocol study designs and key start-up activities in readiness for the initiation of the phase three ShORe and COAST pivotal clinical trials of OPT-302 in wet age-related macular degeneration.